Manufacturer record
Indo Gulf Pharmaceuticals 5.4 Km: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Indo Gulf Pharmaceuticals 5.4 Km was declared Not of Standard Quality in April 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: DIH-227/10, Dexamethasone sodium Phosphate Injection IP (exp Sep 2027). DTL,Dalgate Srinagar kashmir (state lab) found it not of standard quality: The sample does not conform to IP 2022 requirements w.r.t Sterility Test. Listed in the April 2026 alert.
Records by type
1 record linked to Indo Gulf Pharmaceuticals 5.4 Km in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Dexamethasone sodium Phosphate Injection IP | Batch DIH-227/10Mfg Oct 2025 · Exp Sep 2027 | The sample does not conform to IP 2022 requirements w.r.t Sterility TestSterility | DTL,Dalgate Srinagar kashmirState lab | Apr 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.